Skip to content
LexBuild

Agency Information Collection Activities: Submission for OMB Review; Comment Request

---
identifier: "/us/fr/2020-09961"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Agency Information Collection Activities: Submission for OMB Review; Comment Request"
title_number: 0
title_name: "Federal Register"
section_number: "2020-09961"
section_name: "Agency Information Collection Activities: Submission for OMB Review; Comment Request"
positive_law: false
currency: "2020-05-11"
last_updated: "2020-05-11"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2020-09961"
document_type: "notice"
publication_date: "2020-05-11"
agencies:
  - "Health and Human Services Department"
  - "Substance Abuse and Mental Health Services Administration"
fr_citation: "85 FR 27756"
fr_volume: 85
---

#  Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, email or call the SAMHSA Reports Clearance Officer at *[email protected]* or (240) 276-0361.

**Proposed Project: Program Evaluation for Prevention Contract (PEPC)—Strategic Prevention Framework for Prescription Drugs (SPF-Rx) Evaluation (OMB No. 0930-0377)—Revision**

The Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ) aims to complete a cross-site evaluation of SAMHSA's Strategic Prevention Framework for Prescription Drugs (SPF-Rx). SPF-Rx is designed to address nonmedical use of prescription drugs as well as opioid overdoses by raising awareness about the dangers of sharing medications and by working with pharmaceutical and medical communities on the risks of overprescribing. The SPF-Rx program aims to promote collaboration between states/tribes and pharmaceutical and medical communities to understand the risks of overprescribing to youth ages 12-17 and adults 18 years of age and older. The program also aims to enhance capacity for, and access to, Prescription Drug Monitoring Program (PDMP) data for prevention purposes. This request for data collection includes a revision from previously approved OMB instruments.

The SPF-Rx program's indicators of success are reductions in opioid overdoses, reductions in prescription drug misuse, and improved use of PDMP data. Data collected through the tools described in this statement will be used for the national cross-site evaluation of SAMHSA's SPF-Rx program. This package covers continued data collection through 2023. The PEPC team will systematically collect and maintain an Annual Implementation Instrument (AII) and Grantee and Community Level Outcomes data modules submitted by SPF-Rx grantees through the online Data Management System (DMS).

SAMHSA is requesting approval for data collection for the SPF-Rx cross-site evaluation with the following instruments:

*Annual Implementation Instrument (AII)* —The AII is a survey instrument collected yearly to monitor state, tribal entity, and community-level performance, and to evaluate the effectiveness of the SPF-Rx program. This tool is completed by grantees and subrecipient community project directors, and provides process data related to funding use and effectiveness, organizational capacity, collaboration with community partners, data infrastructure, planned intervention targets, intervention implementation, evaluation, contextual factors, training and technical assistance (T/TA) needs, and sustainability.

*Grantee-and Community-Level Outcomes Modules* —These modules collect data on key SPF-Rx program outcomes, including opioid prescribing patterns and provider use of PDMP. Grantees will provide outcomes data at the grantee level for their state, tribal area, or jurisdiction, as well as at the community level for each of their subrecipient communities.

*Grantee-Level Interview* —This qualitative interview will be  administered at the end of the evaluation to obtain information from the grantee project directors on their programs, staffing, populations of focus, infrastructure, capacity, lessons learned, and collaboration.

| Instrument | Number of | Responses per | Total number | Hours per | Total burden |
| --- | --- | --- | --- | --- | --- |
| Annual implementation instrument | 148 | 1 | 148 | 4 | 592 |
| Grantee-Level Outcomes Module | 25 | 1 | 25 | 2.5 | 62.5 |
| Community-Level Outcomes Module | 25 | 4.92 | 123 | 1.25 | 153.75 |
| Grantee-Level Interview | 25 | 1 | 25 | 1.5 | 37.5 |
| FY2021 | 223 |  | 321 |  | 845.75 |
| Annual Implementation Instrument | 148 | 1 | 148 | 4 | 592 |
| Grantee-Level Outcomes Module | 25 | 1 | 25 | 2.5 | 62.5 |
| Community-Level Outcomes Module | 25 | 4.92 | 123 | 1.25 | 154.75 |
| FY2022 | 198 |  | 296 |  | 808.25 |
| Annual Implementation Instrument | 39 | 1 | 39 | 4 | 156 |
| Grantee-Level Outcomes Module | 7 | 1 | 7 | 2.5 | 17.5 |
| Community-Level Outcomes Module | 7 | 4.57 | 32 | 1.25 | 40 |
| FY2023 | 53 |  | 78 |  | 213.5 |

Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to *www.reginfo.gov/public/do/PRAMain* . Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.

Carlos Graham,

Social Science Analyst.